Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : USAMRICD
Deal Size : Undisclosed
Deal Type : Agreement
SMSbiotech Begins Research Partnership with U.S. Army on Chemical Defense
Details : Under theagreement, SMSbiotech and USAMRICD will conduct joint research focused on evaluating the efficacy of SMS cells in mitigating sulfur mustard-induced pulmonary morbidities.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 22, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : USAMRICD
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SMSbiotech Receives Green Light for Phase I Clinical Trial in Australia, Targeting COPD
Details : Small Mobile stem (SMS) cell therapy aims to regenerate damaged alveolar lung tissue, it is currently being investigated for chronic obstructive pulmonary disease (COPD).
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 18, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable